42 Pharmaceutical Technology Edición Sudamérica 2026 - N º203 32. Sadia, M.; So´snicka, A.; Arafat, B.; Isreb, A.; Ahmed, W.; Kelarakis, A.; Alhnan, M.A. Adaptation of pharmaceutical excipients to FDM 3D printing for the fabrication of patient-tailored immediate release tablets. Int. J. Pharm. 2016, 513, 659–668. 33. Zhang, J.; Feng, X.; Patil, H.; Tiwari, R.V.; Repka, M.A. Coupling 3D printing with hot-melt extrusion to produce controlled-release tablets. Int. J. Pharm. 2017, 519, 186–197. 34. Abdella, S.; Youssef, S.H.; Afinjuomo, F.; Song, Y.; Fouladian, P.; Upton, R.; Garg, S. 3D Printing of Thermo-Sensitive Drugs. Pharmaceutics 2021, 13, 1524. 35. Hoffmann, L.; Breitkreutz, J.; Quodbach, J. Fused Deposition Modeling (FDM) 3D Printing of the Thermo-Sensitive Pep-tidomimetic Drug Enalapril Maleate. Pharmaceutics 2022, 14, 2411. 36. Chai, X.; Chai, H.; Wang, X.; Yang, J.; Li, J.; Zhao, Y.; Cai, W.; Tao, T.; Xiang, X. Fused Deposition Modeling (FDM) 3D Printed Tablets for Intragastric Floating Delivery of Domperidone. Sci. Rep. 2017, 7, 2829. 37. Gioumouxouzis, C.I.; Baklavaridis, A.; Katsamenis, O.L.; Markopoulou, C.K.; Bouropoulos, N.; Tzetzis, D.; Fatouros, D.G. A 3D printed bilayer oral solid dosage form combining metformin for prolonged and glimepiride for immediate drug delivery. Eur. J. Pharm. Sci. 2018, 120, 40–52. 38. Goyanes, A.; Chang, H.; Sedough, D.; Hatton, G.B.; Wang, J.; Buanz, A.; Gaisford, S.; Basit, A.W. Fabrication of controlled-release budesonide tablets via desktop (FDM) 3D printing. Int. J. Pharm. 2015, 496, 414–420. 39. Kempin, W.; Domsta, V.; Grathoff, G.; Brecht, I.; Semmling, B.; Tillmann, S.; Weitschies, W.; Seidlitz, A. Immediate Release 3D-Printed Tablets Produced Via Fused Deposition Modeling of a Thermo-Sensitive Drug. Pharm. Res. 2018, 35, 124. 40. Martinez, P.R.; Goyanes, A.; Basit, A.W.; Gaisford, S. Influence of Geometry on the Drug Release Profiles of Stereolithographic (SLA) 3D-Printed Tablets. AAPS PharmSciTech 2018, 19, 3355–3361. 41. Oladeji, S.A.; Dadou, S.M.; Zhao, M.; Li, S.; Jones, D.S.; Andrews, G.P. The development and optimisation of gastro-retentive floating tablets using fused deposition modelling 3D printing. J. Pharm. Pharmacol. 2022, 74, 1450–1466. 42. Pyteraf, J.; Jamróz, W.; Kurek, M.; B ˛ak, U.; Loskot, J.; Kramarczyk, D.; Paluch, M.; Jachowicz, R. Preparation and advanced characterization of highly drug-loaded, 3D printed orodispersible tablets containing fluconazole. Int. J. Pharm. 2023, 630, 122444. 43. Yang, Y.; Wang, H.; Li, H.; Ou, Z.; Yang, G. 3D printed tablets with internal scaffold structure using ethyl cellulose to achieve sustained ibuprofen release. Eur. J. Pharm. Sci. 2018, 115, 11–18. 44. Tabriz, A.G.; Kuofie, H.; Scoble, J.; Boulton, S.; Douroumis, D. Selective Laser Sintering for printing pharmaceutical dosage forms.J. Drug Deliv. Sci. Technol. 2023, 86, 104699. 45. Salmoria, G.V.; Klauss, P.; Zepon, K.M.; Kanis, L.A. The effects of laser energy density and particle size in the selective laser sintering of polycaprolactone/progesterone specimens: Morphology and drug release. Int. J. Adv. Manuf. Technol. 2013, 66, 1113–1118. 46. Deshmane, S.; Kendre, P.; Mahajan, H.; Jain, S. Stereolithography 3D printing technology in pharmaceuticals: A review. Drug Dev. Ind. Pharm. 2021, 47, 1362–1372. 47. Luo, Y.; Wei, X.; Wan, Y.; Lin, X.; Wang, Z.; Huang, P. 3D printing of hydrogel scaffolds for future application in photothermal therapy of breast cancer and tissue repair. Acta Biomater. 2019, 92, 37–47. 48. Shi, X.; Cheng, Y.; Wang, J.; Chen, H.; Wang, X.; Li, X.; Tan, W.; Tan, Z. 3D printed intelligent scaffold prevents recurrence and distal metastasis of breast cancer. Theranostics 2020, 10, 10652–10664. 49. Majrashi, M.; Kotowska, A.; Scurr, D.; Hicks, J.M.; Ghaemmaghami, A.; Yang, J. Sustained Release of Dexamethasone from 3D-Printed Scaffolds Modulates Macrophage Activation and Enhances Osteogenic Differentiation. ACS Appl. Mater. Interfaces 2023, 15, 56623–56638. 50. Alfei, S.; Milanese, M.; Brullo, C.; Valenti, G.E.; Domenicotti, C.; Russo, E.; Marengo, B. Antiproliferative Imidazo-Pyrazole-Based Hydrogel: A Promising Approach for the Development of New Treatments for PLX-Resistant Melanoma. Pharmaceutics 2023, 15, 2425. 51. Diaz-Gomez, L.; Gonzalez-Prada, I.; Millan, R.; Da Silva-Candal, A.; Bugallo-Casal, A.; Campos, F.; Concheiro, A.; Alvarez-Lorenzo, C. 3D printed carboxymethyl cellulose scaffolds for autologous growth factors delivery in wound healing. Carbohydr. Polym. 2022, 278, 118924. 52. Kapoor, D.U.; Pareek, A.; Uniyal, P.; Prajapati, B.G.; Thanawuth, K.; Sriamornsak, P. Innovative applications of 3D printing in personalized medicine and complex drug delivery systems. iScience 2025, 28, 113505. 53. Yasin, H.; Al-Tabakha, M.M.A.; Chan, S.Y. Fabrication of Polypill Pharmaceutical Dosage Forms Using Fused Deposition Modeling 3D Printing: A Systematic Review. Pharmaceutics 2024, 16, 1285. 54. Qi, S. Can we create customized polypills for personalized drug formulation? Expert Opin. Drug Deliv. 2025, 22, 915–918. 55. Windolf, H.; Chamberlain, R.; Breitkreutz, J.; Quodbach, J. 3D Printed Mini-FloatingPolypill for Parkinson’s Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy. Pharmaceutics 2022, 14, 931. 56. Siyawamwaya, M.; du Toit, L.C.; Kumar, P.; Choonara, Y.E.; Kondiah, P.; Pillay, V. 3D printed, controlled release, tritherapeutic tablet matrix for advanced anti-HIV-1 drug delivery. Eur. J. Pharm. Biopharm. 2019, 138, 99–110. 57. FDA. 3D Printing of Medical Devices. Available online: https://www.fda.gov/ medicaldevices/productsandmedicalprocedures/ 3dprintingofmedicaldevices/ default.htm (accessed on 3 October 2025). 58. Alhnan, M.A.; Okwuosa, T.C.; Sadia, M.; Wan, K.W.; Ahmed, W.; Arafat, B. Emergence of 3D Printed Dosage Forms: Opportunities and Challenges. Pharm. Res. 2016, 33, 1817–1832. 59. Warsi, M.H.; Yusuf, M.; Al Robaian, M.; Khan, M.; Muheem, A.; Khan, S. 3D Printing Methods for Pharmaceutical Manufacturing: Opportunity and Challenges. Curr. Pharm. Des. 2018, 24, 4949–4956. 60. FDA. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Available online: https://www.fda.gov/files/drugs/published/ Compounded-Drug-Products-That-Are-Essentially-Copies-of-a-CommerciallyAvailable-Drug-Product-Under-Section-503A-of-the-Federal-Food--Drug--and-Cosmetic-Act-Guidance-for-Industry.pdf (accessed on 3 October 2025). 61. FDA. Abuse-Deterrent Opioids-Evaluation and Labeling, April 2015. Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ abuse-deterrent-opioids-evaluation-and-labeling (accessed on 3 October 2025). 62. Shrank, W.H.; Choudhry, N.K.; Fischer, M.A.; Avorn, J.; Powell, M.; Schneeweiss, S.; Liberman, J.N.; Dollear, T.; Brennan, T.A.; Brookhart, M.A. The epidemiology of prescriptions abandoned at the pharmacy. Ann. Intern. Med. 2010, 153, 633–640.
RkJQdWJsaXNoZXIy NzE4NDM5